Discovery US 2024

7 - 8 November 2024 | Boston, MA

Connecting experts in biology & chemistry to advance small molecule drug discovery

Event Page - Hero Banner 6

Explore Discovery US 2024: Fast-Tracking Novel Target Identification & Validation

As recent technological and pharmacological advances tackle the previously ‘undruggable’, Discovery US returns to support the discovery of novel pharmaceutical modalities beyond the rule of five – including novel degraders, molecular glues, orally-available peptides and radioligands.

The focussed, two-day agenda showcases the key platforms and technologies impacting early drug pipelines, from DNA-encoded libraries and phenotypic screening through to AI algorithms and organoid models. It brings together experts in target discovery and validation from across small & large biopharma organizations to discuss how the newest therapeutic paradigms can overcome historic challenges in drug development and provide optimized, novel drug candidates. Further sessions explore the use of automation to augment drug development and improve your lab productivity, showcasing the competitive advantages that can be gained in drug development through digitalization and robotics.

Discovery US 2024

  • Benefit from our revamped programme for 2024, designed to provide in-depth discussion of the key technologies, modalities & platforms transforming small molecule drug discovery  
  • Discover emerging drug targets beyond the rule of five, from Induced Proximity & Molecular Glues through to siRNAs and orally-available peptides, with case studies on the chemical & biological considerations of developing these complex molecules
  • Enable your lab to operate at peak productivity. Maximize your R&D capabilities with integration of advanced robotics & automation, as well as utilizing AI to augment your drug development

Agenda at a Glance


  • Day One | Track 1: Novel Targets Beyond The Rule Of Fives
  • Day One | Track 2: Novel Models For ADME-Tox Research & Disease Modelling 
  • Day One | Track 3: Augmenting R&D With AI
    • Part 1: AI-Driven Drug Discovery
    • Part 2: Improving Lab Productivity With Robotics & Automation
  • Day Two | Track 1: Innovative Technologies For Hit Identification & Screening
  • Day Two | Track 2: Computational & Medicinal Chemistry
  • Day Two | Track 3: Genomics-Driven Drug Discovery & Bioinformatics

What to Expect

430

leading pharma, biotech & academic delegates

40
hours of presentations, discussions & interactive content
11
hours of networking breaks, including speed networking & refreshments
57
hours of pre-arranged 1-2-1 meetings, facilitating business growth
Interactive Presentations
Exhibition Hall
Networking Drinks
Poster Display
Event App Swapcard

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 75 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Companies Represented Include

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Discovery US 2023: 01 - 02 November 2023, Cambridge, USA

BanuPriya Sridharan
Associate Director,
GSK
Beth Hoffman
Chief Executive Officer,
Origami Therapeutics
Dane Corneil
Director of AI Science,
Benevolent AI
Eric Martin
Director,
Novartis
Joe Franklin
Senior Vice President and Head of Early Discovery,
Anagenex
Lauren Goodrich
VP, Therapeutic Discovery,
Nimble Therapeutics
Nils Hansen
Chief Executive Officer,
Vipergen
Thomas Nittoli
Senior Director,
Regeneron

All Speakers

Aaron Frank
Head of Computational Chemistry,
Arrakis Therapeutics
Abhinav Sharma
Translational Human Models Lead Engineer, Discovery Immunology,
AbbVie
Amir Nikooie
Director,
Eli Lilly
Andrew Doran
Principal Scientist, Automation,
Anagenex
Angel Guzman-Perez
Executive Vice President, Head of Chemistry,
Scorpion Therapeutics
Dave Mauger
Director of Data Science,
Arrakis Therapeutics
Elliott Nickbarg
principal scientist,
merck
Emmanuel Bengio
Senior Machine Learning Scientist,
Recursion Pharmaceuticals
Eric Miele
Associate Director Proteomics,
AstraZeneca
Esther Lee
Associate Director, Medicinal Chemistry,
AstraZeneca
Glenn Kazo
Chief Business Officer,
ARIZ Precision Medicine
Govinda Bhisetti
Vice President,
Cellarity
Hasan Khan
Senior Scientist II,
AbbVie
Hongwu Wang
Principal Scientist,
Merck US
India Ott
Scientist,
AstraZeneca
Istvan Enyedy
Senior Principal Scientist,
UCB
James Hickman
Professor of NanoScience Technology,
University of Central Florida
Jason Ekert
Head of US Discovery Translational Technology,
ucb
Jeannie Lee
Professor of Genetics,
Brigham and Women's Hospital
Jeff Messer
Director Analytics,
GSK
John Santa Maria
Associate Director of Cheminformatics,
FogPharma
Justyna Sikorska
Associate Principal Scientist,
Merck US
Kevin Robbins
Associate Principal Scientist,
AstraZeneca
Kingsley Appiah
Director, In Vitro Pharmacology & HTS,
Dewpoint Therapeutics
Kumar Suresh
Vice President R&D,
Progenra Inc.
Lee Herman
Director Computational Chemistry,
Sunovion Pharmaceuticals
Lucas Mastromatteo
Data Analyst,
GSK
Mark Murcko
Principal,
Dewpoint Therapeutics
Martin Redhead
Executive Director Primary Pharmacology,
Exscientia
Matthew Pharris
Senior Scientist,
UCB
Maximilian Schuier
Senior Global Medical Affairs Leader Neuropsychiatry,
Janssen
Mike Schopperle
CEO,
CureMeta
Paul Scola
Senior Director, Chemistry,
Bristol Myers squobb
Rajeswari Basu
Post Doctoral Scientist,
Stony Brook University
Ralph Mazitschek
Professor,
Brigham and Women's Hospital
Shahar Keinan
Chief Executive Officer,
POLARISqb
Shaun McLoughlin
Principal Research Scientst,
AbbVie
Sina Mohammadi
Principal Scientist,
Merck US
Stefan Peukert
Associate Director,
Novartis
Timothy Smith
Associate Director of Sales,
bit.bio
Tobias Raabe
Research Assistant Professor,
University of Pennsylvania
Tomasz Cierpicki
Professor,
University of Michigan
Xiang Chen
Associate Member,
St Jude Children's Research Hospital
Yuan Wang
Head, Research Analytics,
UCB
Yuxin Liang
Senior Principal Scientific Manager, The NGS Lab,
Genentech

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

New Trailblazer Profluent Launches its AI-enabled OpenCRISPR-1 to Edit the Human Genome

Profluent successfully combined large language models (LLMs) and CRISPR for an open-source AI gene editing project which could reshape CRISPR treatment options.

Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments

Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles.

Newcells Products and Services

From Screening to Success: How Molecular 'Super-Glue' SJ3149, Could Advance Cancer Treatments

Researchers at St Jude Children's Research Hospital used high throughput screening (HTS) to identify SJ3149, a molecular glue degrader. This small molecule demonstrated efficacy across a range of cancer types.

Novo Nordisk Foundation and NVIDIA to Launch a State-of-the-Art National AI Research Centre

Novo Nordisk and NVIDIA join forces to build an AI supercomputer which will be housed in Denmark's national centre for AI innovation.

AI-driven High Throughput Screening for Targeted Drug Discovery

Artificial Intelligence (AI) has significantly transformed high throughput screening (HTS) in drug discovery, increasing efficiency, accuracy, and predictive capabilities in early drug development stages. This research highlights AI's integration into HTS processes, showcasing improved outcomes in hit identification, assay optimization, and target validation, thus accelerating and refining the search for new medications.

Plan Your Visit

Boston Marriott Cambridge
50 Broadway, Cambridge, MA 02142, United States

Public Transportation:

The nearest Bus station is South Station
The nearest Subway station is Kendall/MIT
The nearest Train stations are North Station and South Station
For more information, please click here.

 

By Air: 

Boston Logan International Airport is the nearest airport to the venue – 5 miles from the property. 
For more information, please call +1 800-2356426 or click here.

 

Parking:

On site valet parking: $58.99 (valet with in/out privileges)
Off site self-parking: $48.00 daily (no in/out privileges)

Information regarding accommodation for this event will be added soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery US 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch